Literature DB >> 7678210

Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression.

J C Becker1, A Schwinn, R Dummer, G Burg, E B Bröcker.   

Abstract

Tumour-infiltrating lymphocytes (TIL) have been isolated from early primary melanoma (Clark level III) and expanded in vitro using culture conditions with low concentrations of IL-2 (50 U/ml). Immediately after isolation TIL consisted of mainly CD3+ T cells, and the portion of CD56+ natural killer (NK) cells was below 20%. Fresh TIL cultures could be distinguished by CD25 expression since some contained up to 33%, others less than 5% CD25+ cells. These showed differences in subsequent development during in vitro expansion. CD25-expressing cultures remained stable in their phenotype, whereas the second TIL type showed major changes: CD3 (ca 70-30%) expression decrease, CD25 (ca 5-35%) and CD56 (ca 15-55%) expression increase. The TIL type, which remained dominated by CD3+ T cells, killed autologous tumour cells efficiently (51Cr-release greater than 30% at a E/T ratio of 20:1), which could be blocked by MoAbs against MHC class I molecules. In contrast, the other TIL type exhibited weak cytotoxicity (less than 17% 51Cr-release at an E/T ratio of 20:1) against the autologous tumour. Therefore, the expression of CD25 on freshly isolated TIL is a good marker for tumour specificity of in vitro expanded TIL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678210      PMCID: PMC1554654          DOI: 10.1111/j.1365-2249.1993.tb03365.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes.

Authors:  G Gromo; R L Geller; L Inverardi; F H Bach
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

2.  Activation of peripheral blood T cells via the p75 interleukin 2 receptor.

Authors:  H Yagita; M Nakata; A Azuma; T Nitta; T Takeshita; K Sugamura; K Okumura
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

3.  Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones.

Authors:  G Degiovanni; T Lahaye; M Hérin; P Hainaut; T Boon
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

4.  Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease.

Authors:  M A Alexander; J Bennicelli; D Guerry
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

5.  Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells.

Authors:  Y Ohashi; T Takeshita; K Nagata; S Mori; K Sugamura
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

6.  Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy.

Authors:  J C Becker; R Dummer; A Schwinn; A A Hartmann; G Burg
Journal:  J Immunother (1991)       Date:  1992-08

7.  Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments.

Authors:  M Brennan; P F Davison; H Paulus
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

8.  Mouse melanoma antigen recognized by Lyt-2- and L3T4- cytotoxic T-lymphocytes.

Authors:  K Ono; K Takahashi; Y Hirabayashi; T Itoh; Y Hiraga; M Taniguchi
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

9.  Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2.

Authors:  S Takagi; K Chen; R Schwarz; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

10.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.